Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

449
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
449
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

952
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
952
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

59
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

578
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
578
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect01:26

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

143
The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
143
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

93
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
93

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term prognosis and risk factor-based surveillance strategy for patients with small gastric subepithelial lesion using endoscopic ultrasonography.

Endoscopic ultrasound·2026
Same author

Ift46 deficiency causes renal cyst via enhanced Limk2 through lack of autophagy flux.

Cell communication and signaling : CCS·2026
Same author

Remimazolam vs. midazolam sedation in upper gastrointestinal endoscopy in adults ≥ 65 years: Randomized controlled trial.

European journal of clinical pharmacology·2026
Same author

Application of patient blood management protocol to reduce transfusion rates in limb salvage operations for osteosarcoma: A retrospective study.

Medicine·2026
Same author

Correlation of single leg static postural stability, skeletal muscle mass index, and fear of falling in patients with sarcopenia.

Medicine·2026
Same author

Dihydroartemisinin inhibits metastatic potential and cancer stemness by modulating the miR-200b-BMI-1/VEGF-A axis in ovarian cancer.

Experimental & molecular medicine·2025

Related Experiment Video

Updated: Mar 13, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

12.1K

Recent Trends in ADPKD Research.

Yu Bin Shin1, Jong Hoon Park2

  • 1Molecular Medicine Laboratory, Department of Life systems, Sookmyung Women's University, Cheongpa-ro 47-gil 100, Yongsan-gu, Seoul, 04310, South Korea.

Advances in Experimental Medicine and Biology
|October 13, 2016
PubMed
Summary
This summary is machine-generated.

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common inherited kidney disorder. While no cure exists, research identifies mechanisms and therapies to slow ADPKD progression and manage symptoms.

Keywords:
ADPKDCystDisease mechanismESRDPathogenesisPolycystic kidneyRenal failure

More Related Videos

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
08:46

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

10.3K
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.9K

Related Experiment Videos

Last Updated: Mar 13, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

12.1K
Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
08:46

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

10.3K
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.9K

Area of Science:

  • Nephrology
  • Genetics
  • Molecular Biology

Background:

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a leading inherited cause of kidney failure.
  • Mutations in PKD1 or PKD2 genes are the primary cause of ADPKD.
  • ADPKD leads to progressive cyst growth, end-stage renal disease (ESRD), and renal failure.

Purpose of the Study:

  • To review the current understanding of ADPKD pathogenesis.
  • To explore diagnostic advancements in ADPKD.
  • To summarize therapeutic strategies for slowing ADPKD progression.

Main Methods:

  • Literature review of ADPKD mechanisms and therapies.
  • Analysis of genetic mutations (PKD1, PKD2) and their impact.
  • Synthesis of research on signaling pathways, cell biology, and epigenetics in ADPKD.

Main Results:

  • ADPKD pathogenesis involves complex interactions including growth factors, inflammation, and microRNAs.
  • Diagnostic methods have improved, aiding early detection.
  • Several therapies show promise in slowing disease progression and alleviating symptoms.

Conclusions:

  • ADPKD remains a significant health challenge with no current cure.
  • Understanding molecular mechanisms is key to developing effective treatments.
  • Ongoing research offers hope for improved management and potential future therapies for ADPKD patients.